- Tablets 100 mg
- Tablets 250 mg
Decreases blood glucose by stimulating insulin release from pancreas.
Rapidly absorbed. T max is 2 to 4 h. C max is 30 mcg/mL.
Excreted in breast milk.
Metabolized in the liver.
The t ½ is about 36 h. 80% to 90% is excreted in urine within 96 h (as unchanged drug and as hydroxylated or hydrolyzed metabolites).
Within 1 h.
3 to 5 h.
24 to 60 h.
Special PopulationsRenal Function Impairment
The t ½ is prolonged. Dosage adjustment may be needed.
Indications and Usage
Adjunct to diet to lower blood glucose in patients with non–insulin-dependent diabetes mellitus (type 2) whose hyperglycemia cannot be controlled by diet alone.
Control of neurogenic diabetes insipidus.
Hypersensitivity to sulfonylureas; diabetes complicated by ketoacidosis with or without coma; sole therapy for insulin-independent (type 1) diabetes mellitus; diabetes when complicated by pregnancy.
Dosage and AdministrationAdults Initial dose
PO 250 mg/day in single dose.Elderly Initial dose
PO 100 to 125 mg/day in single dose.Maintenance
PO 100 to 250 mg/day in single dose.Severely Diabetic Adults
PO up to 500 mg/day; avoid doses above 750 mg/day.
Store in cool environment in tightly closed container.
Drug InteractionsAndrogens, anticoagulants, chloramphenicol, clofibrate, fenfluramine, methyldopa, MAOIs, phenylbutazone, probenecid, salicylates, sulfonamides, tricyclic antidepressants, urinary acidifiers
May increase hypoglycemic effect.Beta-blockers, corticosteroids, diazoxide, hydantoins, rifampin, thiazide diuretics, urinary alkalinizers
May decrease hypoglycemic effect.
Laboratory Test InteractionsLFTs
Drug causes elevated results.BUN and creatinine
Drug causes mild to moderate elevations.
Increased risk of CV mortality when compared with patients treated with diet alone.
Allergic skin reactions; eczema; pruritus; erythema; urticaria; morbilliform or maculopapular eruptions; lichenoid reactions; photosensitivity.
GI disturbances (eg, nausea, epigastric fullness, heartburn).
Leukopenia; thrombocytopenia; aplastic anemia; agranulocytosis; hemolytic anemia; pancytopenia; hepatic porphyria.
Cholestatic jaundice; elevated LFTs.
Hypoglycemia; SIADH with water retention and dilutional hyponatremia, especially in patients with CHF or hepatic cirrhosis.
Disulfiram-like reaction; weakness; paresthesia; fatigue; malaise.
Check blood sugar levels frequently and observe for symptoms of hypoglycemia or hyperglycemia and report to health care provider.
Category C . Insulin is recommended to maintain blood glucose levels during pregnancy. Prolonged severe neonatal hypoglycemia can occur if sulfonylureas are administered at time of delivery. If administering to pregnant patient, discontinue 2 days to 4 wk before expected date of delivery.
Excreted in breast milk.
Safety and efficacy not established.
Particularly susceptible to hypoglycemic action. Hypoglycemia can be difficult to recognize in elderly patients.
Use drug with caution and monitor renal function frequently.
Use drug with caution and monitor liver function frequently.
Particularly susceptible to hypoglycemic action.
A sulfonylurea-induced facial flushing reaction may occur when administered with alcohol.
Switch to hypoglycemic agent
When discontinuing chlorpropamide and switching to another oral hypoglycemic agent, exercise caution for 2 wk; prolonged action of chlorpropamide may provoke hypoglycemia.
Hypoglycemia, tingling of lips and tongue, hunger, nausea, lethargy, confusion, agitation, nervousness, tachycardia, sweating, tremor, convulsions, stupor, coma.
- Explain that this medication will not cure disease.
- Emphasize that drug must be taken on daily basis and should not be discontinued abruptly.
- Tell patient that drug may cause GI upset and to take it with food if GI upset occurs.
- Teach patient to self-monitor blood glucose.
- Inform patient to contact health care provider if symptoms of hypoglycemia occur (eg, fatigue, excessive hunger, profuse sweating, numbness of extremities).
- Instruct patient to notify health care provider if symptoms of hyperglycemia occur (eg, excessive thirst or urination, urinary glucose, or ketones).
- Tell patient to report constipation, nausea, vomiting, drowsiness, dizziness, fever, sore throat, rash, or unusual bruising or bleeding to health care provider.
- Inform patient that this drug is not a substitute for exercise and diet control; patient must follow prescribed regimens of diet, exercise, and personal hygiene.
- Instruct patient to inform all health care providers involved in patient's care that this drug is being taken.
- Advise patient not to take any medication (including otc) or drink alcoholic beverages without consulting health care provider; flushing has been reported with chlorpropamide.
- Caution patient to avoid exposure to sunlight and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.
- Advise patient that drug can cause dizziness and to use caution while driving or performing other tasks requiring mental alertness.
- Remind patient to wear medical identification (eg, card, bracelet).
Copyright © 2009 Wolters Kluwer Health.
More Chlorpropamide resources
- Chlorpropamide Prescribing Information (FDA)
- Chlorpropamide Monograph (AHFS DI)
- Diabinese Prescribing Information (FDA)
- chlorpropamide Advanced Consumer (Micromedex) - Includes Dosage Information
- chlorpropamide Concise Consumer Information (Cerner Multum)
- chlorpropamide MedFacts Consumer Leaflet (Wolters Kluwer)